Targeted therapy is the first-and second-line treatment of metastatic renal cell carcinoma. Its mechanism of action can be divided into two categories: inhibition of the vascular endothelial growth factor and its related receptor(VEGF/VEGFR) pathway and inhibition of the mTOR pathway.
靶向治疗是转移性肾癌的一线及二线治疗手段,其药物从作用机制主要分为两类:抗血管内皮生长因子(VEGF)/血管内皮生长因子受体(VEGFR)和抑制mTOR途径。
参考来源 - 肾癌的靶向治疗现状与进展·2,447,543篇论文数据，部分数据来源于NoteExpress
Objective: to establish orthotopic mouse models of human renal cell carcinoma and to separate metastatic or non-metastatic renal cell carcinoma (RCC) from the same source.
目的：建立原位移植裸鼠模型，筛选同一标本来源的转移性和非转移性肾细胞癌(RCC)。
Objective To evaluate the efficacy and safety of sunitinib in the treatment of metastatic renal clear cell carcinoma in our single center.
目的评价单中心舒尼替尼治疗转移性肾脏透明细胞癌的疗效和安全性。
应用推荐